Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study

Article Oncology

A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index

Tateaki Naito et al.

Summary: Anamorelin improves body weight and anorexia-related symptoms in patients with cancer cachexia and a low BMI, with durable efficacy and favorable safety and tolerability.

CANCER (2022)

Add to Collection

Article Oncology

Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial

Ghazal Sadat Askarpour Moezian et al.

Summary: The study aimed to investigate the clinical efficacy of systemic administration of silymarin in managing chemotherapy-induced hepatotoxicity in patients with non-metastatic breast cancer who received the AC-T regimen. Results showed that oral administration of silymarin could significantly reduce hepatotoxicity severity after 1 month of treatment in non-metastatic breast cancer patients treated with the AC-T regimen.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

Add to Collection

Review Immunology

The interplay of immunology and cachexia in infection and cancer

Hatoon Baazim et al.

Summary: This review examines the immunological context of cachexia, discussing its complex relationship with weight loss and tissue wasting in the context of cancer and infection. The potential immunometabolic consequences of cachexia are explored based on newly identified pathways, highlighting the intricate interplay between the immune system and cachexia in malignant and infectious diseases.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Editorial Material Geriatrics & Gerontology

The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.

Hidetaka Wakabayashi et al.

Summary: Anamorelin, a ghrelin receptor agonist that can be taken orally, has been approved for the treatment of cancer cachexia in Japan. Clinical studies have shown that anamorelin can significantly increase lean body mass in patients with cancer, which is important for diagnosing sarcopenia and cachexia in Asia. The approval of anamorelin is expected to change clinical practice in Japan and potentially other countries in the future.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)

Add to Collection

Article Chemistry, Medicinal

Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: A double blind, randomized clinical trial

Roham Salek et al.

Summary: The study showed that using saffron during chemotherapy for breast cancer can alleviate anxiety and depression, while reducing some chemotherapy-related side effects, although it may increase leukopenia. Additionally, there was a trend towards improved survival rates observed in the saffron group.

PHYTOTHERAPY RESEARCH (2021)

Add to Collection

Article Oncology

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines

J. Arends et al.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

KenjiY Morimoto et al.

Summary: This study found that cancer cachexia might be a poor prognostic factor in patients with NSCLC receiving chemoimmunotherapy. Patients with cancer cachexia had a higher frequency of PD-L1 expression >= 50% and shorter progression-free survival, but there was no significant difference in overall survival.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Oncology

A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments

Abdolazim Sedighi Pashaki et al.

Summary: This study demonstrated that coadministration of melatonin during adjuvant chemotherapy and radiotherapy for women with breast cancer effectively reduced fatigue levels associated with the malignant condition and its treatments.

INTEGRATIVE CANCER THERAPIES (2021)

Add to Collection

Review Oncology